
Express Mail Label No.: EU282823117U

Date of Deposit: April 19, 2002



04-22-02 Attorney Docket No.: 21402-224AC (Cura 5.

# T AND TRADEMARK OFFICE

APPLICANTS:

Li et al.

SERIAL NUMBER:

10/023,681

**EXAMINER:** 

Not Yet Assigned

RECEIVED

TECH CENTER 1600/2900

FILING DATE:

December 18, 2001

ART UNIT:

1645

FOR:

Novel Proteins and Nucleic Acids Encoding Same

#### **BOX IDS**

Commissioner for Patents Washington, D.C. 20231

#### TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (2 pages), in duplicate;
- 3. Copies of cited references C1-C27; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21402-224AC (Cura-524AC). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Brian P. Hopkins, Reg. No. 42,669

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: April 19, 2002


TRA 1656942v1

30623

PATENT TRADEMARK OFFICE

Express Mail Label No.: EU282823117US

Date of Deposit: April 19, 2002



## IN THE UNITED STATES TAREET AND TRADEMARK OFFICE

APPLICANTS:

Li et al.

SERIAL NUMBER:

10/023,681

EXAMINER:

Not Yet Assigned

FILING DATE:

December 18, 2001

ART UNIT:

1645

For:

Novel Proteins and Nucleic Acids Encoding Same

**BOX IDS** 

Commissioner for Patents Washington, D.C. 20231

RECEIVED

APR 2 4 2002

TECH CENTER 1600/2900

### INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: U.S.S.N.:

Li et al. 10/023,681

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-224AC (Cura-524AC).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529 Brian P. Hopkins, Reg. No. 42,669

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C. One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: April 19, 2002

TRA 1656932v1

Express Mail N .: EU282823117US Date fD posit: April 19, 2002

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control purpose.

FILE
TIVEL
2002
<sup></sup> 600/2900
7-000

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

,			FOREIGN PATENT DOCUMENTS		
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Asai et al. (1996). "Genomic structure and transcription of a murine odorant receptor gene: differential initiation of transcription in the olfactory and testicular cells." <i>Biochem Biophys Res Commun</i> 221(2): 240-247.
	C2	Ben-Arie et al. (1994). "Olfactory receptor gene cluster on human chromosome 17: possible duplication of an ancestral receptor repertoire." Hum Mol Genet 3(2): 229-235.
	СЗ	Blier (2001). "Pharmacology of rapid-onset antidepressant treatment strategies." <i>J Clin Psychiatry</i> 62(Suppl 15): 12-17.
	C4	Buck and Axel (1991). "A novel multigene family may encode odorant receptors: a molecular basis for odor recognition." <i>Cell</i> <u>65(1)</u> : 175-187.
	C5	Cowburn et al. (1992). "Adenylyl cyclase activity in postmortem human brain: evidence of altered G protein mediation in Alzheimer's disease." <i>J Neurochem</i> 58(4): 1409-1419.
	C6	El Yacoubi et al. (2001). "Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice." <i>Br J Pharmacol</i> 134(1): 68-77.
	C7	Fowler et al. (1996). "Receptor-effector coupling dysfunctions in Alzheimer's disease." <i>Ann N Y Acad Sci</i> 786: 294-304.
	C8	Hebert and Bouvier (1998). "Structural and functional aspects of G protein-coupled receptor oligomerization." Biochem Cell Biol 76(1): 1-11.
	C9	Heinemann et al. (2000). "Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling." <i>J Immunol</i> 165(12): 7224-7233.
	C10	Issel-Tarver and Rine (1996). "Organization and expression of canine olfactory receptor genes." <i>Proc Natl Acad Sci U S A</i> 93(20): 10897-10902.
	C11	Kourie (2001). "Mechanisms of amyloid beta protein-induced modification in ion transport systems: implications for neurodegenerative diseases." <i>Cell Mol Neurobiol</i> <u>21(3)</u> : 173-213.
	C12	Krautwurst et al. (1998). "Identification of ligands for olfactory receptors by functional expression of a receptor library." Cell 95(7): 917-926.
	C13	Lee et al. (2001). "Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required

Express Mail N .: EU282823117US Date f D p sit: April 19, 2002



Page 2 of 2

		OTHER PRIOR AND BATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.  for endothelial cell chemotaxis." Mol Cell 8(3): 693-704.  Malnic et al. (1999). "Combinatorial receptor codes for odors." Cell 96(5): 713-723.  Mark et al. (2000). "G protein modulation of recombinant P/O type calcium chappels by regulators of
		for endothelial cell chemotaxis." Mol Cell 8(3): 693-704.
	C14	Malnic et al. (1999). "Combinatorial receptor codes for odors." Cell 96(5): 713-723.
	C15	Mark et al. (2000). "G protein modulation of recombinant P/Q-type calcium channels by regulators of G protein signalling proteins." <i>J Physiol</i> <u>528</u> (Pt 1): 65-77.
	C16	Monopoli et al. (1998). "Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats." <i>Neuroreport</i> <u>9</u> (17): 3955-3959.
	C17	Online Mendelian Inheritance in Man (OMIM): 164342
	C18	Parmentier et al. (1992). "Expression of members of the putative olfactory receptor gene family in mammalian germ cells." <i>Nature</i> 355(6359): 453-455.
	C19	Perrine et al. (1998). "Cognitive functioning after pallidotomy for refractory Parkinson's disease." <i>J Neurol Neurosurg Psychiatry</i> 65(2): 150-154.
	C20	Rouquier et al. (1998). "A gene recently inactivated in human defines a new olfactory receptor family in mammals." <i>Hum Mol Genet</i> 7(9): 1337-1345.
	C21	Takada et al. (1997). "Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress." Biochem Biophys Res Commun 240(3): 737-741.
	C22	Thomas et al. (1996). "Chemoreceptors expressed in taste, olfactory and male reproductive tissues." Gene <u>178</u> (1-2): 1-5.
	C23	Tranquillini and Reggiani (1999). "Glycine-site antagonists and stroke." Expert Opin Investig Drugs 8(11): 1837-1848. (ABSTRACT ONLY)
	C24	Vanderhaeghen et al. (1997). "Specific repertoire of olfactory receptor genes in the male germ cells of several mammalian species." <i>Genomics</i> 39(3): 239-246.
	C25	Walensky et al. (1998). "Two novel odorant receptor families expressed in spermatids undergo 5'-splicing." <i>J Biol Chem</i> 273(16): 9378-9387.
	C26	Whitehead et al. (2001). "Rho GTPase-dependent transformation by G protein-coupled receptors." Oncogene 20(13): 1547-1555.
	C27	Xie et al. (2000). "Characterization of a cluster comprising approximately 100 odorant receptor genes in mouse." Mamm Genome 11(12): 1070-1078.

•	a copy of this reference is a	not provided as it was prev	iously cited by or submitted to the office in a prior
	application, Serial No	, filed	, and relied upon for an earlier
	filing date under 3		

• 5 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature Date Considered
------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1656843v1